Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.

Emyria Limited

Emyria is involved in healthcare services, focusing on the development of innovative therapies and medical products. Self-described as an investment opportunity.

Metric
Company Name	Emyria Limited
Symbol	EMD
MSH ID	COM:EMYRIA
Market	STOCKS
Sector	Healthcare
Industry	Medical - Healthcare Information Services
Country	AU
Stage
Employee Count
Website	emyria.com
LinkedIn
Founders

Metric
Market Cap	13.33M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.41M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-1.81M
EBITDA	-3.97M
Operating Income	-4.41M
Net Income	-7.32M
EPS	-0.02
Diluted EPS	-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.77
Operating Profit Margin	-1.99
EBITDA Margin	-2.82
Net Profit Margin	-5.20
Return on Equity	-3.09
Return on Assets	-1.92
Return on Capital Employed	-1.37

EMD

COM:EMYRIA

Emyria

Last Close

0.04

22/11 05:10

Market Cap

20.86M

Beta: -

Volume Today

229.57K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.00
P/B Ratio	2.26
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.79
EV Multiple	-1.65

Metric
Days Sales Outstanding	19.59
Days Payables Outstanding	298.06
Days Inventory Outstanding	31.01
Operating Cycle	35.53
Cash Conversion Cycle	-11.68
Asset Turnover	0.41

Metric
Operating Cash Flow	-2.74M
Free Cash Flow	-3.53M
Cash Flow to Debt	-1.72
Operating Cash Flow/Sales	-1.95
Free Cash Flow Yield	-0.19

Metric
Cash & Equivalents	1.00M
Accounts Receivable	35.03K
Inventory
Goodwill	997.73K
Debt to Capitalization	0.76
Debt to Assets	0.13
Current Ratio	0.91
Quick Ratio	0.86

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.27
R&D to Revenue	1.16
SG&A to Revenue